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Background: This study investigated variation in NR1I2 and NR1I3 and its effect on plasma efavirenz levels in HIV/
AIDS patients. Variability in plasma drug levels has largely led research on identifying causative variants in drug
metabolising enzyme (DME) genes, with little focus on the nuclear receptor genes NR1I2 and NR1I3, coding for PXR
and CAR, respectively, that are involved in regulating DMEs.
Methods: 464 Bantu-speaking South Africans comprising of HIV/AIDS patients on efavirenz-based treatment
(n=301) and 163 healthy subjects were genotyped for 6 SNPs in NR1I2 and NR1I3. 32 of the 301 patients had their
DNA binding domains (DBDs) in NR1I2 and NR1I3 sequenced.
Results: Significantly decreased efavirenz plasma concentrations were observed in patients carrying the NR1I3
rs3003596C/C and T/C genotypes (P=0.015 and P=0.010, respectively). Sequencing resulted in the discovery of a
further 13 SNPs, 3 of which are novel variants in the DBD of NR1I2. There were significant differences in the
distribution of NR1I2 and NR1I3 SNPs between South Africans when compared to Caucasian, Asian and Yoruba
population groups.
Conclusion: For the realisation of personalised medicine, PXR and CAR genetic variation should be taken into
consideration because of their involvement in the regulation of DMEs.
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The pregnane X receptor (PXR) and the constitutive
androstane receptor (CAR) are members of the orphan
nuclear receptor (NR) superfamily and function primar-
ily as sensors of xenobiotics by up-regulating the expres-
sion of drug metabolising enzymes (DMEs), facilitating
the elimination of xenobiotics from the body [1,2]. PXR
and CAR are transcriptional regulators of a wide range
of genes whose products metabolise a wide range of
drugs [2,3].
PXR and CAR are localised in the cytoplasm in their
inactive state, bound to histone deacetylase complexes
(HDACs). Upon ligand binding, PXR and CAR dissoci-
ate from the HDACs. PXR translocates into the nucleus* Correspondence: collet.dandara@uct.ac.za
1Division of Human Genetics, Faculty of Health Sciences, University of Cape
Town, Observatory, Cape Town 7925, South Africa
Full list of author information is available at the end of the article
© 2012 Swart et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwhere it heterodimerises with the retinoid X receptor
(RXR), while CAR is nuclear translocated through a
phosphorylation-dependent mechanism and subse-
quently heterodimerises with RXR [4]. In the nucleus,
the heterodimers PXR/RXR and CAR/RXR bind to nu-
clear receptor response elements upstream of genes cod-
ing for DMEs) [4].
NR1I2 gene, which encodes PXR, consists of 10 exons
and is located on chromosome 3q13-21 [5]. The NR1I2
DNA binding domain (DBD) is encoded by exons 3 and
4 whereas exons 5–10 code for the ligand binding do-
main (LBD). The DBD and LBD are separated by a hinge
region encoded by a small portion of exon 5 [5]. Several
SNPs have been reported in NR1I2 and some are asso-
ciated with changes in PXR function. For example,
NR1I2 63396C>T (rs2472677), which is located in a pu-
tative transcription factor binding site, has been asso-
ciated with increased NR1I2 expression in the presencetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression leading to decreased atazanavir (ATV) plasma
concentrations [6-8]. Three SNPs in exon 2 have been
reported, namely NR1I2 52G>A (E18K; rs59371185),
79C>T (P27S; rs12721613) and 106G>A (G36R;
rs12721607). The NR1I2 79T and NR1I2 106A alleles are
associated with decreased NR1I2 expression [5]. Another
SNP, NR1I2 7635A>G (rs6785049), is present in intron 5
and the 7635G allele has been associated with increased
expression of CYP3A4 in the presence of rifampicin [9].
The NR1I3 gene, which encodes CAR, is located on
chromosome 1q21-23, and consists of 9 exons. Twenty-
two unique NR1I3 variants have been described where
each isoform results from a different combination of
splicing events. Some isoforms produce non-functional
proteins due to the presence of nonsense mutations
[10,11]. NR1I3 isoform-3 has been suggested as the
wild-type and produces a 348 amino acid protein [11].
The NR1I3 DBD is encoded by exons 2, 3 and the 5' por-
tion of exon 4 [12]. Previously characterised SNPs in
NR1I3 include NR1I3 rs2307424C>T, of which the
rs2307424T allele has been associated with low efavirenz
plasma concentrations and the NR1I3 rs2307424C/C
genotype has been associated with early discontinuation
of efavirenz-containing anti-retroviral therapy (ART) in
Caucasian HIV/AIDS patients [13].
Genetic characterization of indigenous African popula-
tions is slowly building up. This study aimed to further
contribute to the genetic characterization of African
populations by genotyping NR1I2 and NR1I3 and evalu-
ating the effects of their variants on the response to efa-
virenz treatment in HIV/AIDS Bantu-speaking South
African patients. In order to accelerate discovery of
novel SNPs, the DBD of both NR1I2 and NR1I3 were
targeted for sequencing [1].
Methods
Study subjects
The study cohort consisted of four-hundred and sixty-
four (n=464) Bantu-speaking South Africans made up of
healthy subjects (n=163) and HIV/AIDS patients
(n=301) undergoing efavirenz-based treatment for at
least six months. The subjects were recruited from Gau-
teng and Cape Town. Written informed consent was
obtained and each participant provided demographic in-
formation such as 1) their ethnic group, 2) health status,
3) dietary habits, 4) smoking habits, and 5) home lan-
guage were captured using a questionnaire. The study
was approved by the Research Ethics Committee of the
Faculty of Health Sciences at the University of Cape
Town and the University of Witwatersrand Human Re-
search Ethics Committee, Gauteng, South Africa and
was performed in accordance with the guidelines of the
Helsinki Declaration of 2008.Two blood samples were obtained for DNA extraction
and plasma efavirenz levels, respectively. DNA isolation
was performed according to the method adapted from
Gustafson et al.,[14] or the GenEluteTM Blood Genomic
DNA Kit (Sigma-Aldrich, St. Louis, MO, USA) was used
when blood sample volumes were limited. Steady state
efavirenz plasma levels were available for 137 of the 301
HIV/AIDS patients and were collected 12–16 hours
post-dose. Efavirenz concentrations were determined by
the use of LC/MS/MS (API 4000 triple quadrupole MS/
MS Applied Biosystems, South Africa) according to the
method by Chi et al., [15].
Selection of SNPs and genotyping methods used
Three SNPs in NR1I2 [GenBank: AF364606] and a fur-
ther three SNPs in NR1I3 [GenBank: BC069626.1] were
investigated in this study. The six SNPs were selected
based on previous reports of high minor allele frequen-
cies in African-American and other African populations.
SNPs were genotyped using either SNaPshot mini-
sequencing or the PCR-RFLP method designed for
NR1I2 rs2472677C>T (Additional file 1: Table S1).
PCR amplification was performed using the following
conditions: initial denaturation at 94°C for 3 min, fol-
lowed by 40 cycles of denaturation at 94°C for 30s,
annealing at the specific temperature for each SNP for
30s, primer extension at 72°C for 20-45s depending on
the primer sets and final extension at 72°C for 10 min. A
“MyCycler Thermal cycler” (Bio-Rad, Hercules, USA)
was used and the PCR reaction contained the following
reagents; 50–100 ng of genomic DNA, 1X Green GoTaq
Flexi Reaction Buffer (Promega Corporation, Madison,
USA), 0.20 mM of each of the deoxynucleotide tripho-
sphates (dNTPs) (Bioline, London, UK), 1.5 mM MgCl2
(Promega Corporation, Madison, USA), 40 pmol of the
forward and reverse primers (Integrated DNA Technolo-
gies, Inc., Coralville, USA), 1U of GoTaq Flexi DNA
Polymerase (Promega Corporation, Madison, USA). PCR
amplification was followed by digestion using 3U
Hpy188I (New England BioLabs, Inc., Ipswich) in the
presence of 1X NEBuffer 4 (New England BioLabs, Inc.,
Ipswich) when genotyping for the NR1I2 rs2472677C>T
polymorphism.
SNaPshot multiplex
Five separate PCR amplification reactions were carried
out. PCR products (5 μl) were then pooled for SNaPshot
genotyping. The pooled PCR products were cleaned
using 1.5U shrimp alkaline phosphatase (Fermentas Life
Sciences, Burlington, Canada) and 2U ExonucleaseI (Fer-
mentas Life Sciences, Burlington, Canada) to remove
unincorporated primers and dNTPs. SNaPshot single
base extension was performed using the “GeneAmpW
PCR System 9700 version 3.08” (Applied Biosystems,
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ation at 96°C for 10s, followed by 25 cycles of primer
annealing at 50°C for 5s and primer extension at 60°C
for 30s. To the 1 μl ABI PrismW SNaPshot™ Multiplex
Kit (Applied Biosystems, California, USA), primers (Inte-
grated DNA Technologies, Inc., Coralville, USA) for the
pooled PCR products were added. The clean-up reaction
was repeated using 1U shrimp alkaline phosphatase. An
ABI 3130xl Genetic Analyzer (Applied Biosystems,
Carlsbad, USA) was used for capillary electrophoresis
and GeneMapper© Software version 4.1 (Applied Biosys-
tems, Carlsbad, USA) was used to analyse results.
Identification of novel SNPs
The NR1I2 and NR1I3 DNA binding domains (DBDs)
were sequenced in 32 of the 301 HIV/AIDS patients to
search for novel SNPs. The sequencing reaction used the
ABI PrismW BigDyeW Terminator Cycle Sequencing v3.1
Kit (Applied Biosystems, Carlsbad, CA, USA), which
included 1 μl Terminator mix and 1X Sequencing buffer,
together with the PCR fragment, and 1 μM of the for-
ward or reverse primer. Analysis of the sequencing data
was performed using BioEdit Sequence Alignment Editor
v7.0.0. The novel SNPs were assessed for functional sig-
nificance with the Functional Analysis of Novel SNPs
(FANS) program (http://genepipe.ncgm.sinica.edu.tw/
fans/input.do) [16] and ESE finder v3.0.
Statistical analysis
Statistical analyses were performed using the Graphpad
Prism statistical program (Version 5, GraphPad Software
Inc., San Diego, CA), Statistica v10.0 (StatSoft, USA) and
Phase v2.1 [17-19]. Pearson’s χ2-test and Fisher’s exact
test was used to compare the genotype and allele fre-
quencies between the healthy participants and the HIV/
AIDS patients as well as the allele frequencies in the
South Africans to those of other populations with results
in literature. The SHEsis statistical program was used for
linkage disequilibrium (LD, D’ and r2) [20,21] analysis
and Phase v2.1 for inferring of NR1I2 and NR1I3 haplo-
types. Statistical significance was defined as P <0.05 and
all statistical tests were performed two tailed.
Results
Demographic characteristics
The healthy subjects had a mean age of 35.8 years (SD ±
14.0 years), while the HIV/AIDS patients (consisting of
71 males, 226 females and 4 patients where gender were
not recorded) had a mean age of 41.3 years (SD ±9.3
years). Among the HIV/AIDS patients, efavirenz plasma
concentrations were available in 137 subjects. A sum-
mary of the baseline characteristics of the study cohort is
outlined in Table 1. The efavirenz plasma concentrationin the South African HIV/AIDS patients showed a large
degree of variation (36-fold), ranging between 0.59 and
22 μg/mL, suggesting extensive inter-individual variabil-
ity in efavirenz drug metabolism and disposition.
Genotype frequencies
Genotype frequencies were compared between the
healthy subjects and HIV/AIDS patients for the six
SNPs, three each in NR1I2 and NR1I3, genotyped using
SNaPshot or PCR-RFLP. The genotypes of the healthy
subjects were all in HWE (P>0.05) for the six SNPs.
However, the NR1I2 rs3732356T>G (P=0.020) genotype
frequencies deviated from HWE in the HIV/AIDS
patients. Polymorphic variation was observed in all six
SNPs and all genotypes were observed in both healthy
subjects and HIV/AIDS patients except for the NR1I2
rs6785049A/A genotype, which was absent in the HIV/
AIDS patients and the NR1I3 rs2307424T/T genotype,
which was not observed in both the healthy subjects and
HIV/AIDS patients (Table 2). The distribution of NR1I2
rs3732356T>G and NR1I2 rs6785049G>A genotypes
were significantly different between the healthy subjects
and HIV/AIDS patients (P=0.031 and 0.002, respectively)
(Table 2). Although gender differences are known to re-
sult in differences in drug disposition, no association of
gender with plasma efavirenz levels were observed in
this study with average plasma efavirenz levels of 5.25
μg/mL and 4.43 μg/mL in males and females, respect-
ively (P=0.307).
Variants discovered through targeted sequencing of
NR1I2 and NR1I3 DNA binding domains (DBD) in 32 HIV/
AIDS patients
Targeted sequencing of the DBDs in NR1I2 [GenBank:
AF364606] and NR1I3 [GenBank: BC069626.1] in 32
HIV/AIDS patients identified a total of 13 genetic var-
iants (Table 3). Only three of these were novel variants
discovered in the DBD of NR1I2 (36726T>C, in intron 1;
36857G>A and 36905C>T, both in exon 2) (Additional
file 2: Figure S1). Using the FANS program, the func-
tional significance of the novel SNPs was predicted.
While NR1I2 36726T>C change was predicted to be of
little functional significance, NR1I2 36857A variant was
associated with increased binding affinity of SRp40 spli-
cing proteins compared to the NR1I2 36857G variant.
Correlation of NR1I2 and NR1I3 variants with plasma
efavirenz concentrations, change in treatment regimens
and effects of CYP2B6 516G>T SNP
The NR1I3 rs3003596C/C and T/C genotypes were asso-
ciated with significantly reduced plasma efavirenz con-
centrations compared to the NR1I3 rs3003596T/T
genotype with P-values of 0.015 and 0.010, respectively
and remained significant after Bonferroni’s correction
Table 1 Demographic characteristics of the healthy participants and HIV/AIDS patients
HIV/AIDS patients (n=301)
Gender ratio (Male: Female) 1:3.8







Mean BMI, kg/m2 (range) 23.23 ±4.74 (11.7-40.6)
Average viral load at baseline, copies/ml (range) 26917.71 ±27133.50 (25–98400)





Average plasma efavirenz concentration, μg/mL (range) 4.64 (0.59 – 22)
Mean Haemoglobin level, IU/l (range) 11.58 ±2.14 (5.4-16.3)
Median AST level, IU/l (range) 32 (15 – 228)
Median ALT level, IU/l (range) 23.5 (6 – 176)
Healthy subjects (n=163)
Gender ratio (Male: Female) 1:2.3
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with significant P<0.017 (Figure 1D). Three of the
twenty-two (14%) individuals with the rs3003596C/C
genotype had plasma efavirenz concentrations above 4
μg/mL, while twenty-four of the fifty (48%) individuals
with the rs3003596T/T genotype had plasma efavirenz
concentrations above 4 μg/mL. The trend towards
reduced plasma efavirenz levels associated with NR1I3
rs3003596C/C and T/C genotypes remained despite
stratification according to CYP2B6 G516T genotypes
(Figure 2). CYP2B6 is the main enzyme involved in the
metabolism of efavirenz and the CYP2B6 516T variant is
associated with reduced CYP2B6 activity and inversely,
increased plasma efavirenz levels. The effect of the
rs3003596C variant is clearly demonstrated in Figure 2C
where, in the absence of CYP2B6 substantial activity,
the variant is associated with significantly decreased
efavirenz levels. This points to possible increased NR1I3
expression in the presence of the NR1I3 rs3003596Cvariant, eliciting its effects through other enzymes that
participate in efavirenz metabolism.
Although not statistically significant, NR1I2 rs3732356G/
G genotype was associated with high plasma efavirenz
concentrations while NR1I3 rs2502815T/T and NR1I3
rs2307424C/T genotypes were associated with reduced
plasma efavirenz levels. It was observed that the NR1I2
rs3732356G/G genotype was associated with the least
likelihood of changing treatment regimens at 3, 6 and
12 months (0%, 0%, 0%), while 4%, 11%, 24% and 3%, 6%,
21% in patients with the T/T and T/G genotypes, respect-
ively, had their treatment regimens changed (Table 4).
However, this finding could have been influenced by the
small sample size (n=9) of the NR1I2 rs3732356G/G
genotype group (Figure 1A). It was also observed that
NR1I3 rs2307424C/T genotype was associated with the
highest number (12%, 20% and 32%) of patients switching
from efavirenz-based treatment regimen at all three time
intervals, respectively (Table 4).
Table 2 Comparison of the genotype frequencies between control subjects and HIV/AIDS patients
SNP Genotype Location/functional effect Healthy subjects HIV/AIDS patients Global
p-
value
n (freq) n (freq)
NR1I2 rs3732356T>G T/T Intron 3 95 (0.605) 162 (0.549) 0.031
T/G 50 (0.318) 123 (0.417)
G/G 12 (0.076) 10 (0.034)
NR1I2 rs2472677C>T C/C Intron 1, Disrupts HNF3B TFB site 57 (0.368) 97 (0.365) 0.917
C/T 75 (0.484) 133 (0.500)
T/T 23 (0.148) 36 (0.135)
NR1I2 rs6785049G>A G/G Intron 5 128 (0.853) 264 (0.950) 0.002
G/A 21 (0.140) 14 (0.050)
A/A 1 (0.007) 0 (0.000)
NR1I3 rs2307424C>T C/C Exon 5, Pro180Pro 138 (0.879) 270 (0.915) 0.216
C/T 19 (0.121) 25 (0.085)
NR1I3 rs3003596T>C T/T Intron 3 51 (0.325) 100 (0.341) 0.659
T/C 72 (0.459) 140 (0.478)
C/C 34 (0.217) 53 (0.181)
NR1I3 rs2502815C>T C/C Intron 3 88 (0.564) 180 (0.610) 0.173
C/T 53 (0.340) 100 (0.339)
T/T 15 (0.096) 15 (0.051)
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levels could possibly act through increased transcription
of PXR or CAR and therefore increased transcription of
downstream DME genes such as CYP2B6 and CYP1A2
leading to increased efavirenz clearance through metab-
olism. Thus, the NR1I3 rs2307424T variant may result in
the decrease in efavirenz levels to concentrations that
are too low for effective viral suppresion, necessitating
the change in treatment regimen when physicians noteTable 3 NR1I2 and NR1I3 genetic variants in 32 HIV/AIDS pati
NR1I3 DNA binding domains
SNP ID Location/Functional effect
NR1I2 rs12721601T>C Previously reported, Intron 1
NR1I2 rs59371185G>A Previously reported, Exon 2, Glu18Lys
NR1I2 rs12721613C>T Previously reported, Exon 2, Pro27Ser
NR1I2 rs1464603C>T Previously reported, Intron 2, Disrupts H
NR1I2 rs1464602C>T Previously reported, Intron 2
NR1I2 rs80320762G>A Previously reported, Intron 2
NR1I2 rs12721616C>T Previously reported, Intron 2
NR1I2 rs112813596G>A Previously reported, Intron 3
NR1I3 rs35205211C>G Previously reported, Exon 4, Ala86Ala
NR1I3 rs34161743C>T Previously reported, Exon 4, Arg97Trp
NR1I2 36726T>C Novel, Intron 1
NR1I2 36857G>A* Novel, Exon 2
NR1I2 36905C>T Novel, Exon 2
Position is noted according to the NR1I2 gene sequence [GenBank: AF364606], *Allepoor viral load decreases. On the other hand, variants
associated with increased plasma efavirenz could be act-
ing through decreased transcription of DMEs and are
associated with treatment changes due to ADRs. As con-
firmed from the patient records, the major cause for
treatment change in the NR1I3 rs2307424C/T genotype
group was ineffective viral suppresion, while the major
reason in the NR1I3 rs2307424C/C genotype group was
adverse drug events. Although the amino acid change isents following targeted sequencing of the NR1I2 and
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Figure 1 A-H: Effects of NR1I2 and NR1I3 variation on plasma efavirenz concentration. Only significant P-values are indicated.





Figure 2 A-C: Effects of NR1I3 rs3003596 and CYP2B6 G516T
variation on plasma efavirenz concentration. A) NR1I3 rs3003596
stratified by CYP2B6 516G/G. B) Stratified by CYP2B6 516G/T. C)
Stratified by CYP2B6 516T/T. Only significant P-values are indicated.
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affect the rate of transcription and to some extent pro-
tein folding [22].
Allele frequencies and their distribution in different
populations
The frequencies of the genetic variants detected in
NR1I2 and NR1I3 among South African subjects were
compared to allele frequencies in populations of Cauca-
sian, Asian and Yoruba origin obtained from HapMap or
dbSNP (Table 5). Statistically significant differences were
observed between the allele frequencies in the South Af-
rican cohort and the Caucasian, Asian and Yoruba
populations for eleven of the twelve SNPs in NR1I2 and
NR1I3 (P<0.05). The Bantu-speaking South African
population showed differences in the distribution of 8
SNPs when compared to the Yoruba population (Table 5),
which renders problematic the use of one African popu-
lation to predict drug response in another.
Haplotype analysis
Haplotype frequencies were compared between the
healthy subjects and the HIV/AIDS patients. The haplo-
type frequencies in NR1I2 were significantly different be-
tween the healthy subjects and HIV/AIDS patients
(P=0.015) (Table 6). However, the difference was margin-
ally significant where the haplotype analysis was cor-
rected for multiple testing with significant P<0.017. By
observation, the NR1I2 T-G-G haplotype (with respect
to rs2472677-rs3732356-rs6785049), which occurs in
about 3% of the HIV/AIDS patients, was associated with
efavirenz levels greater than 4 μg/mL, and this may in-
fluence treatment regimen change (Figure 3A).
Discussion
Many factors, including environmental and genetic fac-
tors, determine how individual patients respond to
therapeutic drugs. Pharmacogenetics is concerned with
understanding individual genetic variability and how it
affects response to treatment. Most of the early work
has focused on DME genes because of their direct in-
volvement in conversion of drugs and their removal
from the body. However, in order to gain a better under-
standing, variation in the NRs that affect the regulation
of DMEs was investigated. This research provides a win-
dow into how the variation in the NRs, PXR and CAR,
can indirectly affect plasma drug levels and ultimate re-
sponse to treatment. The report also documents the fre-
quencies of variants for these two genes in the South
African population and adds to the growing literature on
the genetic characterization of African populations
[23,24]. To our knowledge, this is the first report on
baseline frequencies for the six SNPs in NR1I2 and
NR1I3 in a Bantu-speaking South African population.
Table 4 Frequency of HIV/AIDS patients changing ART regimens within 3, 6 or 12 months post-initiation of treatment
Gene ARV regimen or Genotype Treatment initiation (n) 3 months 6 months 12 months
ARV regimen
3TC_TDF_EFV 9 0.11 0.11 0.22
AZT_3TC_EFV 11 0.00 0.09 0.27
d4T_3TC_EFV 222 0.03 0.08 0.22
NR1I2
rs3732356T/T 156 0.04 0.11 0.24
rs3732356T/G 117 0.03 0.06 0.21
rs3732356G/G 9 0.00 0.00 0.00*
rs2472677C/C 92 0.05 0.06 0.22
rs2472677C/T 128 0.02 0.11 0.23
rs2472677T/T 36 0.03 0.11 0.17
rs6785049G/G 251 0.03 0.08 0.22
rs6785049G/A 14 0.00 0.07 0.29
NR1I3
rs2307424C/C 257 0.02 0.07 0.21
rs2307424C/T 25 0.12 0.20 0.32
rs3003596T/T 96 0.04 0.08 0.23
rs3003596T/C 132 0.03 0.10 0.20
rs3003596C/C 52 0.02 0.06 0.23
rs2502815C/C 169 0.02 0.09 0.22
rs2502815C/T 98 0.05 0.08 0.22
rs2502815T/T 15 0.00 0.00 0.20
*None of the subjects carrying the NR1I2 rs3732356G/G genotype changed their treatment regimen.
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and comparison to other world populations
The genotype frequencies between the healthy subjects
and HIV/AIDS patients differed significantly for the
NR1I2 rs6785049G>A and NR1I2 rs3732356T>G SNPs
(P=0.002 and 0.031, respectively). The difference in
genotype frequencies for the NR1I2 rs3732356T>G SNP
between the healthy subjects and HIV/AIDS patients
may be explained by the deviation from HWE in the
HIV/AIDS patients (P=0.020). Among the HIV/AIDS
patients, the NR1I2 rs6785049A/A genotype was not
observed and the rs6785049A variant occurred at a fre-
quency of 2.5% compared to the 7% among healthy sub-
jects. On the other hand, the NR1I2 rs3732356G allele
frequency was higher among HIV/AIDS patients (48%)
compared to healthy subjects (22%). The above findings
lead us to postulate that PXR may have a role, not only
in the metabolism of drugs, but also indirectly in signal-
ling pathways active during acute stages of infection. Gu
et al., [25] showed that NF-kB directly interacts with the
DBD of RXR; this in turn prevents RXR binding to its
consensus DNA sequences and PXR.
NR1I2 rs2472677C>T, NR1I2 rs6785049G>A and
NR1I3 rs2307424C>T SNPs displayed significant differ-
ences in allele frequencies between the South African
population and the Caucasian and Asian populations. Asa result, therapeutic drugs such as efavirenz that are
ligands for NRs, may result in different drug effects in dif-
ferent populations. Similarly, African populations cannot
be regarded as homogeneous due to the genetic diversity
existing between the sub-populations. For example, three
SNPs in NR1I3 and NR1I2 rs6785049 showed a significant
difference in allele frequencies between the South African
population and the Yoruba population from Ibadan,
Nigeria.
The SNPs in NR1I2, rs3732356T>G, rs2472677C>T
and rs6785049G>A, as well as in NR1I3, rs2307424C>T,
rs3003596T>C and rs2502815C>T, displayed no evidence
of LD, which is in contrast to the strong LD for NR1I3
rs2502815C>T and NR1I3 rs2307424C>T reported in a
Caucasian population (D'=1.00; P= 0.01) [26]. This find-
ing is consistent with the weak LD reported in African
populations, due to the large degree of genetic diversity
in African populations [27].
Comment on drug discovery and relevance of this
knowledge
Sequencing of the NR1I2 and NR1I3 DBDs identified
several previously characterised SNPs as well as three
novel variants in the NR1I2 DBD. The allele frequency
(0.016) of the NR1I2 52A allele (rs59371185) observed in
the 32 sequenced South African individuals was similar
Table 5 Comparison of the allele frequencies between the South Africans and other populations
SNP ID Minor
allele












G 0.234 0.254 0.033** N/A 0.000**
NR1I2
rs2472677C>T
T 0.351 0.356 0.636** 0.544* N/A
NR1I2
rs6785049G>A
A 0.040 0.000** 0.673** 0.453** N/A
NR1I3
rs2307424C>T
T 0.047 0.119** 0.336** 0.512** N/A
NR1I3
rs3003596T>C
C 0.416 0.612** 0.407 0.535 0.500
NR1I3
rs2502815C>T
T 0.230 0.406** 0.248 0.442** 0.500**
n=32# n=226 n=226 n=86
NR1I2
rs12721601T>C
C 0.016 0.008 N/A N/A N/A
NR1I2
rs59371185G>A
A 0.016 0.000 N/A N/A N/A
NR1I2
rs12721613C>T
T 0.064 0.183* 0.000* 0.000* N/A
NR1I2
rs1464603C>T
T 0.016 N/A 0.292** 0.325** 0.000
NR1I2
rs1464602C>T
T 0.313 0.186* 0.717** 0.675** 0.667**
NR1I2
rs80320762G>A
A 0.048 0.144* N/A N/A N/A
NR1I2
rs12721616C>T
T 0.219 0.042** N/A N/A N/A
NR1I2
rs112813596G>A
A 0.016 N/A N/A N/A 0.000
NR1I3
rs35205211C>G
G 0.032 N/A N/A N/A 0.005
NR1I3
rs34161743C>T
T 0.016 N/A N/A N/A 0.005
NR1I2 36726T>C# C 0.078 N/A N/A N/A N/A
NR1I2 36857G>A# A 0.016 N/A N/A N/A N/A
NR1I2 36905C>T# T 0.031 N/A N/A N/A N/A
N/A = not available; *allele frequencies statistically significantly different from the South Africans (P<0.05), **allele frequencies statistically significantly different
from the South Africans (P<0.001), #Sequencing according to the NR1I2 gene sequence [GenBank: AF364606] with the allele change for NR1I2 36857G>A according
to the reverse sequence.
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Coast and sub-Saharan Africa [9,28]. The NR1I2 70C>T
SNP was observed at a frequency of 0.063 in the
sequenced samples, but has however, been reported at
frequencies of 0.126 and 0.002 in sub-Saharan Africans
and Caucasians, respectively [9,28]. NR1I2 36726T>C is
predicted to be of little significance, since it is present in
an intron and is not situated within a GT-AG splice site.
Although NR1I2 36857G>A and NR1I2 36905C>T in
exon 2 are both synonymous amino acid substitutions,
they may be associated with differential PXR expression
due to codon usage [22]. The NR1I2 36905T variant was
also predicted to affect the structure of PXR. Furtheranalysis (with ESE finder v3.0) revealed that NR1I2
36857A affects the binding affinity of the SRp40 splicing
protein, which regulates pre-ribosome assembly and
transport. Destabilisation of the DBD of NRs is likely to
influence the binding of these NRs to promoter regions
of target DMEs and possibly alter transcription and ex-
pression. Alternatively spliced NR1I2 mRNA isoforms
can differ in their patterns of expression, biological func-
tion (either gain- or loss-of-function), activation of target
genes like DMEs, DNA binding and tissue-specific ex-
pression [29], which may contribute to inter-individual
variability in NR1I2 expression and ultimately efavirenz
metabolism.
Table 6 Comparison of the haplotype frequencies between the healthy subjects and the HIV/AIDS patients
Haplotypes Healthy subjects n (freq) HIV/AIDS patients n (freq) Efavirenz levels (μg/mL)* Global p-value#
NR1I2 haplotypes [rs2472677-rs3732356-rs6785049]
C-T-A 7 (0.025) 6 (0.012) 2.13
C-T-G 109 (0.367) 190 (0.379) 4.00
C-G-G 64 (0.216) 114 (0.226) 6.69 0.015
T-T-A 16 (0.052) 6 (0.011) 4.94
T-T-G 96 (0.321) 172 (0.343) 4.23
T-G-G 6 (0.019) 13 (0.026) 4.55
NR1I3 haplotypes [rs2307424-rs2502815-rs3003596]
C-C-T 153 (0.489) 310 (0.530) 4.97
C-C-C 58 (0.187) 122 (0.208) 3.45
C-T-T 7 (0.023) 8 (0.013) 3.53 0.424
C-T-C 75 (0.240) 121 (0.207) 3.87
T-C-T 14 (0.045) 22 (0.037) 4.42
T-C-C 4 (0.012) 3 (0.005) 1.89
*Efavirenz levels are for the HIV/AIDS patients only; #Global p-value is for comparison of haplotype frequencies between healthy subjects and HIV/AIDS patients.
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development of diagnostic tools
A significantly low average plasma efavirenz concentra-
tion was observed among patients with the NR1I3
rs3003596C/C and T/C genotypes compared to patients
with the rs3003596T/T genotype (P=0.015 and P=0.010,
respectively), using a dominant genetic model. The low
efavirenz concentrations may point to possible functional
effects of the change on CAR, expression or activity,
and regulation of multiple target genes encoding DMEs.
Efavirenz induces CYP2B6 activity primarily through
CAR and genetic variation in NR1I3 may therefore sig-
nificantly influence efavirenz plasma concentrations via
the induction of CYP2B6. Due to the availability of
resources in Western and Asian countries, these popu-
lations have been well studied in comparison to the
African populations [30,31]. Thus, most drug-discoveryA   
Figure 3 A-B: Effects of NR1I2 and NR1I3 haplotypes on plasma efavir
NR1I2 C-T-T and NR1I3 T-C-C haplotypes were only observed once and thusand development is premised on Caucasian and Asian
populations, and as a result, new drugs may make it to
the market without having been exposed to most of the
genetic variability within African populations. The effect
of this variability only becomes obvious when adverse
drug events are noticed [30]. For example, the ART
guidelines initially established by the World Health
Organization, on which the South African guidelines are
modelled, was based on clinical data obtained primarily
from Caucasian and Asian individuals. Understanding
the consequence of genetic variation in NR1I2 and NR1I3
adds to the pharmacogenetics knowledge and improves
the move towards personalised medication. This data,
taken together with variation in DMEs that metabolise
efavirenz (e.g. CYP2B6 and CYP2A6), may aid in the
designing of appropriate genotyping assays that could
prove useful in individualized efavirenz dosing regimens.B
enz concentration. The therapeutic range for efavirenz is shown.
excluded from the analysis.
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The finding of novel variants in NR1I2 after sequencing
a very small portion of the DBD is further testimony that
there is still “missing” genetic heritability that can be dis-
covered when sequencing as many African genomes as
possible. In addition, our data highlights the role
(though indirect) that variation in NR genes can play in
drug treatment response.
Additional files
Additional file 1: Table S1. PCR-RFLP and SNaPshot genotyping of
SNPs in NR1I2 and NR1I3 and sequencing of NR1I2 and NR1I3 DNA
binding domains.
Additional file 2: Figure S1. Chromatograms of the novel variants at
position NR1I2 36726T>C in intron 1, NR1I2 36857G>A (allele change
according to the reverse sequence) in exon 2 and NR1I2 36905C>T in
exon 2.
Competing interests
All authors declare that they have no competing interest.
Authors’ contributions
MS carried out 40% the molecular genetic studies and drafted the
manuscript. HW carried out 60% of the molecular genetic studies. YR and PS
both carried out the LC/MS/MS analysis of plasma efavirenz concentration.
RR contributed towards reagents and equipment. CD conceived of the
study, designed, coordinated the study, assisted with statistical data analysis
and helped to draft the manuscript and approved the final version. All
authors read and approved the final manuscript.
Acknowledgements
We thank the South African Medical Research Council (MRC), the National
Research Foundation of South Africa (NRF) and the University of Cape Town
for grants supporting CD’s research programme; the Poliomyelitis Research
Foundation (PRF) for funding. We also thank Professor Patrick McPhail for
facilitating sample collection from the Clinical HIV Research Unit at Themba
Lethu Clinic, Helen Joseph Hospital, Johannesburg, South Africa.
Author details
1Division of Human Genetics, Faculty of Health Sciences, University of Cape
Town, Observatory, Cape Town 7925, South Africa. 2Department of Clinical
Pharmacology, Faculty of Health Sciences, University of Cape Town,
Observatory, Cape Town 7925, South Africa.
Received: 9 May 2012 Accepted: 12 November 2012
Published: 22 November 2012
References
1. Wang H, LeCluyse EL: Role of orphan nuclear receptors in the regulation
of drug-metabolising enzymes. Clin Pharmacokinet 2003, 42(15):1331–1357.
2. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D: Nuclear receptors in the
multidrug esistance through the regulation of drug-metabolizing
enzymes and drug transporters. Biochem Pharmacol 2012, 56:2153–2157.
3. Piedade R, Schaeffeler E, Winter S, Asimus S, Schwab M, Ashton M, Burk O,
Gil JP: PXR variants and artemisinin use in Vietnamese subjects:
Frequency distribution and impact on the inter-individual variability of
CYP3A induction by artemisinin. Antimicrob Agents Chemother 2012,
83:1112–1126.
4. Handschin C, Meyer UA: Induction of drug metabolism: the role of
nuclear receptors. Pharmacol Rev 2003, 55(4):649–673.
5. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD,
Maurel P, Relling M, Brimer C, et al: The human pregnane X receptor:
genomic structure and identification and functional characterization of
natural allelic variants. Pharmacogenetics 2001, 11(7):555–572.
6. Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB:
A human immunodeficiency virus protease inhibitor is a novelfunctional inhibitor of human pregnane X receptor. Drug Metab Dispos
2008, 36(3):500–507.
7. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA:
The human orphan nuclear receptor PXR is activated by compounds
that regulate CYP3A4 gene expression and cause drug interactions.
J Clin Invest 1998, 102(5):1016–1023.
8. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-
Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A:
Identification of a human nuclear receptor defines a new signaling
pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998,
95(21):12208–12213.
9. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I,
Brinkmann U, Eichelbaum M, Wojnowski L, et al: Natural protein variants of
pregnane X receptor with altered transactivation activity toward
CYP3A4. Drug Metab Dispos 2001, 29(11):1454–1459.
10. Auerbach SS, Ramsden R, Stoner MA, Verlinde C, Hassett C, Omiecinski CJ:
Alternatively spliced isoforms of the human constitutive androstane
receptor. Nucleic Acids Res 2003, 31(12):3194–3207.
11. Lamba JK, Lamba V, Yasuda K, Lin YS, Assem M, Thompson E, Strom S,
Schuetz E: Expression of constitutive androstane receptor splice variants
in human tissues and their functional consequences. J Pharmacol Exp
Ther 2004, 311(2):811–821.
12. Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ: Transcriptional
analysis of the orphan nuclear receptor constitutive androstane receptor
(NR1I3) gene promoter: identification of a distal glucocorticoid response
element. Mol Endocrinol 2003, 17(1):42–55.
13. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner
JR, Brockmeyer NH, Bieniek B, et al: Cytochrome P450 2B6 (CYP2B6) and
constitutive androstane receptor (CAR) polymorphisms are associated
with early discontinuation of efavirenz-containing regimens. J Antimicrob
Chemother 2011, 66(9):2092–2098.
14. Gustafson S, Proper JA, Bowie EJ, Sommer SS: Parameters affecting the
yield of DNA from human blood. Anal Biochem 1987, 165(2):294–299.
15. Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT: Simultaneous
determination of five HIV protease inhibitors nelfinavir, indinavir,
ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
J Pharm Biomed Anal 2002, 30(3):675–684.
16. Liu CK, Chen YH, Tang CY, Chang SC, Lin YJ, Tsai MF, Chen YT, Yao A:
Functional analysis of novel SNPs and mutations in human and mouse
genomes. BMC Bioinformatics 2008, 9(Suppl 12):S10.
17. Stephens M, Donnelly P: A comparison of bayesian methods for
haplotype reconstruction from population genotype data. Am J Hum
Genet 2003, 73(5):1162–1169.
18. Stephens M, Scheet P: Accounting for decay of linkage disequilibrium in
haplotype inference and missing-data imputation. Am J Hum Genet 2005,
76(3):449–462.
19. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype
reconstruction from population data. Am J Hum Genet 2001, 68(4):978–989.
20. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage
disequilibrium, haplotype construction, and genetic association at
polymorphism loci. Cell Res 2005, 15(2):97–98.
21. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y: A partition-ligation-
combination-subdivision EM algorithm for haplotype inference with
multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell
Res 2009, 19(4):519–523.
22. Gu W, Zhou T, Ma J, Sun X, Lu Z: The relationship between synonymous
codon usage and protein structure in Escherichia coli and Homo
sapiens. Biosystems 2004, 73(2):89–97.
23. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M:
Genetic variants in CYP (−1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and
ABCB1 genes in a black South African population: a window into
diversity. Pharmacogenomics 2011, 12(12):1663–1670.
24. Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L: Analysis
of pharmacogenetic traits in two distinct South African populations.
Hum Genomics 2011, 5(4):265–282.
25. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y:
Role of NF-kappaB in regulation of PXR-mediated gene expression: a
mechanism for the suppression of cytochrome P-450 3A4 by
proinflammatory agents. J Biol Chem 2006, 281(26):17882–17889.
26. Oliver P, Lubomirov R, Carcas A: Genetic polymorphisms of CYP1A2,
CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive
Swart et al. BMC Medical Genetics 2012, 13:112 Page 12 of 12
http://www.biomedcentral.com/1471-2350/13/112androstane receptor in 207 healthy Spanish volunteers. Clin Chem Lab
Med 2010, 48(5):635–639.
27. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins
J, DeFelice M, Lochner A, Faggart M, et al: The structure of haplotype
blocks in the human genome. Science 2002, 296(5576):2225–2229.
28. Svard J, Spiers JP, Mulcahy F, Hennessy M: Nuclear receptor-mediated
induction of CYP450 by antiretrovirals: functional consequences of
NR1I2 (PXR) polymorphisms and differential prevalence in whites and
sub-Saharan Africans. J Acquir Immune Defic Syndr 2010, 55(5):536–549.
29. Keightley MC: Steroid receptor isoforms: exception or rule? Mol Cell
Endocrinol 1998, 137(1):1–5.
30. Tishkoff SA, Williams SM: Genetic analysis of African populations: human
evolution and complex disease. Nat Rev Genet 2002, 3(8):611–621.
31. Lonjou C, Collins A, Morton NE: Allelic association between marker loci.
Proc Natl Acad Sci U S A 1999, 96(4):1621–1626.
doi:10.1186/1471-2350-13-112
Cite this article as: Swart et al.: PXR and CAR single nucleotide
polymorphisms influence plasma efavirenz levels in South African HIV/
AIDS patients. BMC Medical Genetics 2012 13:112.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
